Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Why Have the Hot Biotechs of a Year Ago Cooled Down?

This article was originally published in Start Up

Executive Summary

Most hot technologies have tended to fall into one of three categories: (i) incremental improvements that address a single segment of the drug discovery process but that fail to actually increase the number of clinical candidates produced by the drug discovery apparatus when considered as a whole; (ii) spellbinding technologies that have yet to show a practical, proven application to drug discovery; and (iii) technologies that are useful but that can't seem to be packaged within a successful corporate business model.

You may also be interested in...



Why Clinical Trials Fail Unexpectedly

Is there an explanation for the recent spate of biotech Phase II and Phase III clinical trial failures? It's almost impossible to give general reasons for specific clinical failures. Several hypotheses, borrowed from the tenets of behavioral finance, however, may help explain some recent, unanticipated later-stage setbacks. They may also support other studies that suggest that small biotech companies fail more often in clinical development than their larger biotech and pharma brethren.

Why Investors Adopt Orphans

Venture-backed biotech companies are increasingly seeking to commercialize drugs that qualify for orphan drug protection from the FDA; is this business model a good idea?

Can Anyone Make Money from Biomarkers?

Biomarkers are being used now across the whole pharmaceutical value chain, but it's unlikely we'll see a surge in the number of VC-backed biomarker discovery start-ups until the business models are proven.

Topics

UsernamePublicRestriction

Register

SC090553

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel